<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04216849</url>
  </required_header>
  <id_info>
    <org_study_id>DFSC-2019(CR)-06</org_study_id>
    <nct_id>NCT04216849</nct_id>
  </id_info>
  <brief_title>Clinical Study of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Type 2 Diabetic Nephropathy</brief_title>
  <official_title>Clinical Study of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Type 2 Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai East Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai East Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was a 48-week multicenter, randomized, double-blind, placebo-controlled trial that&#xD;
      included 8 weeks of pre-screening and lifestyle education, 32 weeks of treatment, and 16&#xD;
      weeks of follow-up.To observe the efficacy and safety of umbilical cord mesenchymal stem cell&#xD;
      infusion in Chinese patients with type 2 diabetic nephropathy who received traditional&#xD;
      hypoglycemic therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was a 48-week multicenter, randomized, double-blind, placebo-controlled trial that&#xD;
      included 8 weeks of pre-screening and lifestyle education, 32 weeks of treatment, and 16&#xD;
      weeks of follow-up.We plan to recruit 54 subjects，which were divided into experimental group&#xD;
      and control group. The volunteers of the experimental group will be given peripheral&#xD;
      intravenously a dose of 1.5*10^6/kg human umbilical cord mesenchymal stem cell (HUC-MSC) at&#xD;
      0,8,16,24,32 week. The control group will be given the same dose of saline. Then&#xD;
      centralization visit was conducted every 8 weeks until the 48th week.The primary end points&#xD;
      include estimated glomerular filtration rate and urinary albumin creatinine ratio(UACR). The&#xD;
      secondary end points include HbA1C,plasma insulin and C-peptide, and insulin dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>UACR</measure>
    <time_frame>48weeks after treatment</time_frame>
    <description>urinary albumin creatinine ratio</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>48weeks after treatment</time_frame>
    <description>HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin/C peptide</measure>
    <time_frame>48weeks after treatment</time_frame>
    <description>serum level of insulin/C peptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin dosage</measure>
    <time_frame>48weeks after treatment</time_frame>
    <description>insulin dosage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR</measure>
    <time_frame>48weeks after treatment</time_frame>
    <description>estimated glomerular filtration rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Type 2 Diabetes With Renal Manifestations</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The volunteers of the experimental group will be given peripheral intravenously a dose of 1.5*10^6/kg human umbilical cord mesenchymal stem cells at 0,8,16,24,32 week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group will be given the same dose of saline containing human albumin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human umbilical cord mesenchymal stem cells</intervention_name>
    <description>human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group</description>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>Saline solution containing human serum albumin will be infused to the control group</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (in brief):&#xD;
&#xD;
          -  Type 2 diabetes mellitus&#xD;
&#xD;
          -  Diabetes duration≤20 years&#xD;
&#xD;
          -  18.5kg/m^2 ≤ BMI&lt; 30 kg/m^2&#xD;
&#xD;
          -  7.5%≤HbA1C≤10%&#xD;
&#xD;
          -  UACR≥30mg/gCr&#xD;
&#xD;
          -  eGFR ≥45/milliliter/1.73m^2&#xD;
&#xD;
        Exclusion Criteria (in brief):&#xD;
&#xD;
          -  Type 1 diabetes mellitus&#xD;
&#xD;
          -  tumor history&#xD;
&#xD;
          -  Other causes of chronic kidney disease&#xD;
&#xD;
          -  Abnormal liver function&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhongming Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai East Hospital, Shanghai Tongji University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Congrong Wang, MD</last_name>
    <phone>+86-021-38804518</phone>
    <email>wcr601@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhongming Liu, MD</last_name>
    <phone>+86-021-38804518</phone>
    <email>liu.zhongmin@tongji.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200124</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Congrong Wang, MD</last_name>
      <phone>+86-021-38804518</phone>
      <email>wcr601@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 17, 2019</study_first_submitted>
  <study_first_submitted_qc>December 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2020</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>human umbilical cord mesenchymal stem cells</keyword>
  <keyword>type 2 diabetic nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

